Shyh-Han Tan Ph.D.

Education

National University of Singapore, B.Sc. (Hons)
National University of Singapore, Ph.D.

Biography

Dr. Tan earned his B.Sc. and Ph.D. from the National University of Singapore, where his doctoral research focused on the transcriptional regulation of Human Papillomavirus type-16 under Dr. Hans-Ulrich Bernard. He completed his postdoctoral training with Dr. Mary Dasso at NICHD, NIH, characterizing the role of SUMO isopeptidase SUSP1 in nuclear body formation. He transitioned to prostate cancer research with Dr. Marja Nevalainen at Georgetown University and later at Thomas Jefferson University.

Dr. Tan’s early work demonstrated that ERG inhibits prostate epithelial cell differentiation and promotes EMT by repressing ANXA2 transcription. His findings highlighted a reciprocal correlation between ERG and ANXA2 expression in prostate tumors, suggesting ANXA2’s potential as a prognostic marker. He also led the development of a specific ERG monoclonal antibody, simplifying the detection of TMPRSS2-ERG fusion in prostate cancer by IHC. This antibody has been instrumental in studying the clonal progression of ERG-positive tumors and stratifying prostate cancers by ERG status.

Currently, Dr. Tan’s research focuses on identifying genomic signatures contributing to prostate cancer disparities, particularly among African American men. As part of the APOLLO Cancer Moonshot initiative, he co-leads a team exploring the proteogenomics of prostate cancer to identify predictive biomarkers and therapeutic targets for metastatic progression in diverse populations. His ongoing projects use innovative approaches to understand intratumoral heterogeneity and phenotypic diversity in prostate cancer. These include digital spatial profiling of cancer driver genes and immune biomarkers, studying epigenomic regulation of EMT and tumor progression, and integrating digital pathology, proteogenomics, and clinico-pathological data using deep learning to predict survival and identify cancer subtypes.

Representative Bibliography

Schafer C, Young D, Singh H, Jayakrishnan R, Banerjee S, Song Y, Dobi A, Petrovics G, Srivastava S, Srivastava S, Sesterhenn IA, Chesnut GT, Tan SH. Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens. J Immunol Methods. 2023 Jul;518:113493. doi: 10.1016/j.jim.2023.113493. Epub 2023 May 16. PMID: 37196930.

Jayakrishnan R, Schafer C, Tan SH. Prostate cancer autoantibodies - applications in diagnosis, prognosis, monitoring disease progression and immunotherapy. Am J Clin Exp Urol. 2023 Apr 15;11(2):79-102. PMID: 37168942; PMCID: PMC10165224.

Gesztes W, Schafer C, Young D, Fox J, Jiang J, Chen Y, Kuo HC, Mwamukonda KB, Dobi A, Burke AP, Moul JW, McLeod DG, Rosner IL, Petrovics G, Tan SH, Cullen J, Srivastava S, Sesterhenn IA. Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. Sci Rep. 2022 Mar 30;12(1):5404. doi: 10.1038/s41598-022-08826-5. PubMed PMID: 35354846; PubMed Central PMCID: PMC8967869.

Kohaar I, Zhang X, Tan SH, Nousome D, Babcock K, Ravindranath L, Sukumar G, Mcgrath-Martinez E, Rosenberger J, Alba C, Ali A, Young D, Chen Y, Cullen J, Rosner IL, Sesterhenn IA, Dobi A, Chesnut G, Turner C, Dalgard C, Wilkerson MD, Pollard HB, Srivastava S, Petrovics G. Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes. Nat Commun. 2022 Mar 15;13(1):1361. doi: 10.1038/s41467-022-28945-x. PubMed PMID: 35292633; PubMed

Tan SH, Young D, Chen Y, Kuo HC, Srinivasan A, Dobi A, Petrovics G, Cullen J, Mcleod DG, Rosner IL, Srivastava S, Sesterhenn IA. Prognostic features of Annexin A2 expression in prostate cancer. Pathology. 2021 Feb;53(2):205-213. doi: 10.1016/j.pathol.2020.07.006. Epub 2020 Sep 20. PubMed PMID: 32967771; PubMed Central PMCID: PMC7855416.

Tan SH, Petrovics G, Srivastava S. Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. Int J Mol Sci. 2018 Apr 22;19(4). doi: 10.3390/ijms19041255. Review. PubMed PMID: 29690565; PubMed Central PMCID: PMC5979433.

Petrovics G, Li H, Stümpel T, Tan SH, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, Cheng J, Dalgard CL, Zhang S, Csabai I, Kagan J, Takeda D, Loda M, Srivastava S, Scherf M, Seifert M, Gaiser T, McLeod DG, Szallasi Z, Ebner R, Werner T, Sesterhenn IA, Freedman M, Dobi A, Srivastava S. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine. 2015 Dec;2(12):1957-64. doi: 10.1016/j.ebiom.2015.10

Tan SH, Furusato B, Fang X, He F, Mohamed AA, Griner NB, Sood K, Saxena S, Katta S, Young D, Chen Y, Sreenath T, Petrovics G, Dobi A, McLeod DG, Sesterhenn IA, Saxena S, Srivastava S. Evaluation of ERG responsive proteome in prostate cancer. Prostate. 2014 Jan;74(1):70-89. doi: 10.1002/pros.22731. Epub 2013 Sep 21. PubMed PMID: 24115221; PubMed Central PMCID: PMC4075339.

Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010 Sep;13(3):228-37. doi: 10.1038/pcan.2010.23. Epub 2010 Jun 29. PubMed PMID: 20585344; PubMed Central PMCID: PMC3010744.